New Case Series on Umbilical Tissue in Plantar Fascia Applications Demonstrates Clinical Reproducibility
PR Newswire
PENSACOLA, Fla., June 10, 2026
Case Series by Dr. Robert Parker, DPM, Published in Archives of Clinical and Biomedical Research Reports Statistically Significant NPRS & WOMAC Improvement in Patients with Plantar Fascia Defects Who Had Previously Failed Standard-of-Care Treatment
PENSACOLA, Fla., June 10, 2026 /PRNewswire/ -- Regenative Labs, an FDA-registered manufacturer of cryopreserved Wharton's Jelly allografts, today announced the publication of a new peer-reviewed case series in the Archives of Clinical and Biomedical Research documenting clinical outcomes in seven patients with plantar fasciosis who received Wharton's Jelly allograft as part of a multimodal regenerative protocol after failing standard-of-care treatment. Authored by Robert Parker, DPM, FACFAS, FAENS, of Parker Foot and Ankle in Houston, Texas, alongside co-authors from Regenative Labs, the study represents the 17th peer-reviewed publication in Regenative Labs' clinical evidence library — and the second peer-reviewed case series focused on plantar fascia applications.
